Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2015
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 14 Jul 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2019 as reported by ClinicalTrials.gov record.